SCLAREOL OR SCLAREOLIDE FOR USE IN THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
The present disclosure relates to the field of personal care and more particularly to a method for preventing or treating inflammatory skin conditions including atopic dermatitis and seborrheic dermatitis which comprises applying to the skin a composition comprising an active agent selected among sclareol, sclareol-like, sclareolide or sclareolide-like and a physiologically acceptable carrier. Another object of the present invention is a method for improving the aspect of inflammatory prone skin, which comprises applying to the skin a composition comprising an active agent selected among sclareol, sclareol-like, sclareolide or sclareolide-like and a physiologically acceptable carrier.
1 . A method for improving the aspect of inflammatory prone skin which comprises applying to the skin a composition comprising an active agent selected among sclareol, sclareol-like, sclareolide or sclareolide-like and a physiologically acceptable carrier.
2 . The method of claim 1 wherein the active agent is the sclareolide in a concentration ranging from 0.001% to 0.2% by weight, relative to the total weight of the composition.
3 . The method of claim 1 wherein the active agent decreases the growth of Malassezia species and preferably the growth of Malassezia restricta.
4 . The method of claim 1 wherein the active agent reduces the redness of the skin.
5 . The method of claim 1 wherein the active agent improves skin barrier function.
6 . The method of claim 1 wherein in skin cells keratin 10 expression and total lipid content are increased and interleukin-8 expression is decreased.
7 . The method of claim 1 wherein the composition is in a form suitable for topical application.
8 . The method of claim 1 wherein the composition a is in the form of a liquid, a lotion, an aerosol, a cream, a gel or an ointment.
9 . A method for preventing or treating inflammatory skin conditions which comprises applying to the skin a composition comprising an active agent selected among sclareol, sclareol-like, sclareolide or sclareolide-like and a physiologically acceptable carrier.
10 . The method of claim 9 wherein the active agent is the sclareolide in a concentration ranging from 0.001% to 0.2% by weight, relative to the total weight of the composition.
11 . The method of claim 9 wherein the active agent decreases the growth of Malassezia species and preferably the growth of Malassezia restricta.
12 . The method of claim 9 wherein inflammatory skin conditions are dermatitis selected among irritant contact dermatitis, allergic contact dermatitis, atopic dermatitis, psoriasis and seborrheic dermatitis.
13 . The method of claim 9 wherein the active agent reduces the redness of the skin and improves skin barrier function.
14 . The method of claim 9 wherein in skin cells keratin 10 expression and total lipid content are increased and interleukin-8 expression is decreased.
15 . The method of claim 9 wherein the composition is in a form suitable for topical application and preferably in the form of a liquid, a lotion, an aerosol, a cream, a gel or an ointment.